Cushing syndrome presents with a wide array of symptoms, many of which result from prolonged exposure to elevated cortisol ...
A mathematical model suggests that existing HPA-targeting drugs failed in clinical trials for mood disorders because the ...
Corcept Therapeutics' long-term goal is $3 billion revenue by 2029, driven by the new drug Relacorilant. Click here to read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback